Jubilant Pharma Limited plans to sell its 25.8% equity stake in Sofie Biosciences Inc. for about USD 139.43 million, including preferred returns, as a result of the merger agreement with Trilantic Capital Partners. The merger is subject to regulatory approvals and closing conditions.